Efficacy News and Research

RSS
Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

Aastrom Biosciences reports third quarter 2010 FY results

Aastrom Biosciences reports third quarter 2010 FY results

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Novel imaging techniques improve post heart attack survival rates in mouse model

Novel imaging techniques improve post heart attack survival rates in mouse model

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Chemical changes in genetic material regulate activity of many genes

Chemical changes in genetic material regulate activity of many genes

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

Icagen reports revenues of $1.5M, net loss of $3.2M for first-quarter 2010

Icagen reports revenues of $1.5M, net loss of $3.2M for first-quarter 2010

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

MicroStockProfit.com releases NexMed investment report

MicroStockProfit.com releases NexMed investment report

MMI-USA expands worldwide patent, trademark programs

MMI-USA expands worldwide patent, trademark programs

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.